Celcuity Inc. cotiza a 63.62 USD y tiene una capitalización bursátil de $3.1B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and t…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-05 |
|---|---|---|---|---|
| Real | — | $-1.07 | — | $-0.86 |
| Estimado | $-1.51 | $-1.08 | $-1.08 | $-0.89 |
| Sorpresa | — | +0.9% | — | +3.4% |
| Métrica | CELC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -176.1% | -40.4% | -135.7% |
| ROA | -38.0% | -32.0% | -5.9% |
| Current Ratio | 10.55 | 2.84 | +7.71 |
| Debt / Equity | 1.37 | 0.28 | +1.09 |